Theranostic Intratumoral Convection-Enhanced Delivery of 124 I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.266365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Neeta Pandit-Taskar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; pandit-n@mskcc.org. Hauptthemen laut MEDLINE: Brain Stem Neoplasms, Iodine Radioisotopes, Diffuse Intrinsic Pontine Glioma, Radiometry. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using 124I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody. We report the detailed pharmacokinetics and dosimetry results of intratumoral delivery of 124I-omburtamab.
Methods
Forty-five DIPG patients who received 9.0-370.7 MBq of 124I-omburtamab intratumorally via CED underwent serial brain and whole-body PET/CT imaging at 3-5 time points after injection within 4, 24-48, 72-96, 120-144, and 168-240 h from the end of infusion. Serial blood samples were obtained for kinetic analysis. Whole-body, blood, lesion, and normal-tissue activities were measured, kinetic parameters (uptake and clearance half-life times) estimated, and radiation-absorbed doses calculated using the OLINDA software program.
Results
All patients showed prominent activity within the lesion that was retained over several days and was detectable up to the last time point of imaging, with a mean 124I residence time in the lesion of 24.9 h and dose equivalent of 353 ± 181 mSv/MBq. Whole-body doses were low, with a dose equivalent of 0.69 ± 0.28 mSv/MBq. Systemic distribution and activities in normal organs and blood were low. Radiation dose to blood was very low, with a mean value of 0.27 ± 0.21 mGy/MBq. Whole-body clearance was monoexponential with a mean biologic half-life of 62.7 h and an effective half-life of 37.9 h. Blood clearance was biexponential, with a mean biologic half-life of 22.2 h for the rapid α phase and 155 h for the slower β phase.
Conclusion
Intratumoral CED of 124I-omburtamab is a novel theranostics approach in DIPG. It allows for delivery of high radiation doses to the DIPG lesions, with high lesion activities and low systemic activities and high tumor-to-normal-tissue ratios and achieving a wide safety margin. Imaging of the actual therapeutic administration of 124I-omburtamab allows for direct estimation of the therapeutic lesion and normal-tissue-absorbed doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; pandit-n@mskcc.org.
- Department of Radiology, Weill Cornell Medical College, New York, New York.
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Pandit-Taskar, N., Zanzonico, P. B., Grkovski, M., Donzelli, M., Vietri, S. M., Horan, C., Serencsits, B., Prasad, K., Lyashchenko, S., Kramer, K., Dunkel, I. J., & Souweidane, M. M. (2024). Theranostic Intratumoral Convection-Enhanced Delivery of 124 I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266365
Vancouver
Pandit-Taskar N, Zanzonico PB, Grkovski M, Donzelli M, Vietri SM, Horan C, et al. Theranostic Intratumoral Convection-Enhanced Delivery of 124 I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266365
BibTeX
@article{PanditTaskar2024,
author = {Pandit-Taskar, Neeta and Zanzonico, Pat B and Grkovski, Milan and Donzelli, Maria and Vietri, Scott M and Horan, Christopher and Serencsits, Brian and Prasad, Kavya and Lyashchenko, Serge and Kramer, Kim and Dunkel, Ira J and Souweidane, Mark M},
title = {Theranostic Intratumoral Convection-Enhanced Delivery of 124 I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.266365}
}
EUVIMED